Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice

BACKGROUND: Dose reduction (DR) of adalimumab, etanercept and ustekinumab has proven to be (cost-)effective in psoriasis patients with low disease activity. Further implementation is needed to establish application of DR for eligible patients. OBJECTIVES: To evaluate the implementation of protocoliz...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Schoot, L.S., Janssen, J.J., Bastiaens, M.T., de Boer-Brand, A., Christiaansen-Smit, C., Enomoto, D.N.H., Hovingh, R., Tupker, R.A., Seyger, M.M.B., Verhoef, L.M., van den Reek, J.M.P.A., de Jong, E.M.G.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013325/
https://www.ncbi.nlm.nih.gov/pubmed/36867069
http://dx.doi.org/10.1080/09546634.2023.2186728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013325/
https://www.ncbi.nlm.nih.gov/pubmed/36867069
http://dx.doi.org/10.1080/09546634.2023.2186728

Ejemplares similares